Sermorelin is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH).

Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant..

SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN).

Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

Senktide is a potent, selective agonist of neuromedin K3 (NK3) receptor (EC50 =0.5-3 nM), less potently agonizes the NK1 receptor (EC50=35 µM) and is without effect on the NK2 receptor..

Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.

SEN1269 is a novel potent Aβ aggregation inhibitor that binds to monomeric Aβ1-42 with Kd of 4.4 uM, protects neuronal cell lines against an Aβ1-42 insult with IC50 of 15 uM.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A.

Semapimod (CNI 1493.

Semapimod (CNI 1493.

Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.

Seliforant (SENS-111, SENS111) is a novel potent, selective histamine H4 receptor antagonist..

Selgantolimod is a novel toll-​like receptor TLR8 modulator for the treatment of HIV infection..

Selective reverse transcriptase inhibitor. Exhibits 100-fold selectivity for HIV reverse transcriptase over DNA polymerase α.

Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM For AMPA, kainate and NMDA receptors respectively). Neuroprotective.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR..

Secnidazole (Flagentyl)

SecinH3 is a selective cytohesin inhibitor with IC50 of 2.4 μM, 5.4 μM, 5.4 μM, 5.6 μM, 5.6 μM, and 65 μM for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, and yGea2-S7, respectively.

Secalciferol

SDZ 220-581 is a potent, competitive NMDA receptor antagonist with pKi of 7.7, fully protects against maximal electroshock seizures (MES) at oral doses of 10 mg/kg in rats and in mice. .

SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SDZ 220-581 Hcl is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SD-1029 (NSC 371488) is a potent inhibitor of Stat3 activation, suppresses EGFP-Stat3 nuclear translocation at 10 uM in both BHK-21 and U2-OS cells.

Scytonemin is a marine natural product that inhibits PLK1 with IC50 of 2 uM against recombinant enzyme, shows similar potentcy for Myt1, Chk1,Cdk1/cyclin B and PKCβ2, less potent against PKA and Tie2.

Sclerotigenin is a natural diazepine originally isolated from P. sclerotigenum that acts as an insect growth regulator.1 It reduces the growth rate of first instar H. zea larvae by 42% relative to controls when administered in the standard test diet at 20

SCH-527123 is a potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively.